| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [Y. K. H., Z. W., R. A. G.], Radiation Oncology [J-H. H., W. H. M.], and Neurology [S. L. P.], UCLA School of Medicine, Los Angeles, California 90024, and Department of Experimental Medicine, University of Roma "La Sapienza," Rome, Italy [L. C.]
We used a modified colony survival assay to measure the sensitivity to ionizing radiation of more than 50 lymphoblastoid cell lines from normal individuals and from patients with ataxia-telangiectasia, Nijmegen breakage syndrome variants, and X-linked agammaglobulinemia. All of these disorders are associated with an increased frequency of cancer. Lymphoblastoid cell lines from patients with ataxiatelangiectasia complementation groups A, C, D, and E; ATFresno; Nijmegen breakage syndrome variants V1 and V2; and X-linked agammaglobulinemia showed marked radiosensitivity, whereas ataxia-telangiectasia heterozygotes were similar to controls. Friedreich's ataxia is not associated with increased cancer risk; lymphoblastoid cell lines from two such patients showed normal radiosensitivity. Taken together, these results suggest that some forms of X-ray sensitivity and cancer susceptibility share a common mechanism, such as an enzyme that is necessary both for the repair of radiation damage to DNA and for gene rearrangements during V(D)J recombination.
1 This work was supported by the U.S. Department of Energy Grant 87ER60548, the Ataxia-Telangiectasia Medical Research Foundation, the A-T Medical Research Trust, US PHS Core Grant CA16042 to the Jonsson Comprehensive Cancer Center at UCLA, and the Italian C.N.R. Projetto Finaliizatto A.C.R.O. 92-02160-39.
2 To whom requests for reprints should be addressed, at Department of Pathology, UCLA School of Medicine, Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90024-1732.
Received 2/22/94. Accepted 4/ 5/94.
This article has been cited by other articles:
|
|
 |
|
  M. F. Lavin, N. Gueven, S. Bottle, and R. A. Gatti Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia Br. Med. Bull., June 23, 2007; (2007) ldm012v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peron, Q. Pan-Hammarstrom, K. Imai, L. Du, N. Taubenheim, O. Sanal, L. Marodi, A. Bergelin-Besancon, M. Benkerrou, J.-P. de Villartay, et al. A primary immunodeficiency characterized by defective immunoglobulin class switch recombination and impaired DNA repair J. Exp. Med., May 14, 2007; 204(5): 1207 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. W. Butch, H. H. Chun, S. A. Nahas, and R. A. Gatti Immunoassay to Measure Ataxia-Telangiectasia Mutated Protein in Cellular Lysates Clin. Chem., December 1, 2004; 50(12): 2302 - 2308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zi Yin, D. P. Frush, L. F. Donnelly, and R. H. Buckley Primary Immunodeficiency Disorders in Pediatric Patients: Clinical Features and Imaging Findings Am. J. Roentgenol., June 1, 2001; 176(6): 1541 - 1552. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Shigeta, M. Takagi, D. Delia, L. Chessa, S. Iwata, Y. Kanke, M. Asada, M. Eguchi, and S. Mizutani Defective Control of Apoptosis and Mitotic Spindle Checkpoint in Heterozygous Carriers of ATM Mutations Cancer Res., June 1, 1999; 59(11): 2602 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Peretz, R. Jensen, R. Baserga, and P. M. Glazer ATM-dependent expression of the insulin-like growth factor-I receptor in a pathway regulating radiation response PNAS, February 13, 2001; 98(4): 1676 - 1681. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
